ClinicalTrials.gg
CompletedNCT01196052Updated Oct 6, 2014Results posted

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

A Phase 2 interventional study of Trastuzumab emtansine in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 44 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Enrollment
21st of 56
153 · median 103
Started
2010
with 2 others
Phase 2
26 of 56
9 open now
Registered
13th of 56
by date
Lead sponsor
18 of 56
Hoffmann-La Roche

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 21st largest by enrollment, is one of 3 that started in 2010, is one of 26 in phase 2, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age.
  • Locally advanced, inflammatory, or early stage, unilateral, and confirmed invasive breast cancer documented at a local laboratory (patients with inflammatory breast cancer must be able to have a core needle ).
  • Herceptin (HER)2-positive tumor, confirmed by central testing using immunohistochemistry (IHC) and in situ hybridization (ISH) methods.
  • Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of or adjuvant treatment.
  • For women of and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of or 2 effective forms of non-hormonal contraception by the patient and/or partner. Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients should use condoms for the duration of the study. Specific country requirements will be followed.
  • Negative results of serum pregnancy test for premenopausal women of reproductive capacity and for women \< 12 months after menopause.
  • Patients may enroll before or after AC/FEC chemotherapy has completed.
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic, biochemistry, and cardiac assessments.

Exclusion criteria

Exclusion Criteria:

  • Stage IV breast cancer or bilateral breast cancer.
  • Pregnant or breastfeeding women.
  • History of other within the previous 5 years, except contralateral breast cancer and ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS), appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with outcome similar to those mentioned above.
  • Radiation therapy, immunotherapy, or biotherapy within 5 years before study enrollment; non-cardiotoxic chemotherapy for malignancy treated > 5 years before study enrollment is allowed. Patients receiving AC/FEC in a similar fashion to the study treatment prescribed for or neoadjuvant treatment of breast cancer will be allowed to enroll in the study after the completion of their AC/FEC. No other prior history of cardiotoxic chemotherapy is allowed.
  • Active cardiac history.
  • Current chronic daily treatment with oral or equivalent.
  • Patients with severe dyspnea at rest or requiring supplementary oxygen therapy.
  • Active, unresolved infections at screening.
  • (HIV), virus (HBV), or virus (HCV) infection.
  • Major surgery within 4 weeks before enrollment that is unrelated to the breast cancer.
  • Patients for whom concomitant radiotherapy + T-DM1 may be yet radiation therapy is planned.
  • Known to any of the study drugs or derivatives, including murine proteins.
  • Grade ≥ 2 peripheral neuropathy at Baseline.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Trastuzumab emtansine

    Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.

    Drug: Trastuzumab emtansine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment

    A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association \[NYHA\] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of \< 50%.

    Time frame: Baseline to 12 weeks after the start of trastuzumab emtansine treatment

  2. Adverse Events, LVEF Function, and Deaths

    The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF \< 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported.

    Time frame: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

Secondary outcomes

  1. Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment

    Time frame: From the start to the end of concurrent radiotherapy (up to 51 weeks)

  2. Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment

    Time frame: From the start to the end of concurrent hormonal therapy (up to 51 weeks)

  3. Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment

    Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy.

    Time frame: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

  4. Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay

    Time frame: From the start to the end of radiotherapy treatment (up to 51 weeks)

  5. Percentage of Participants With a Pathological Complete Response

    Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery.

    Time frame: Day of surgery

  6. Disease-free Survival at Month 12

    Disease-free survival was defined as the time from date of first protocol treatment for adjuvant patients or date of surgery for neoadjuvant patients to disease recurrence, occurrence of invasive contralateral breast cancer, other second primary cancer (excluding non-breast second primary), or death, whichever occurred first.

    Time frame: From the start of trastuzumab emtansine for adjuvant patients and from the date of surgery for neoadjuvant patients to 12 months later

07

Results

Posted Jun 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Emtansine
Started153
Received trastuzumab emtansine148
Completed130
Not completed23
Withdrew: Adverse event9
Withdrew: Lost to follow-up1
Withdrew: Noncompliance to protocol requirements2
Withdrew: Reason not specified5
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryPercentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment

A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association \[NYHA\] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of \< 50%.

Time frame:
Baseline to 12 weeks after the start of trastuzumab emtansine treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment0 (0.00 to 2.45)
PrimaryAdverse Events, LVEF Function, and Deaths

The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF \< 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported.

Time frame:
From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
Reported as:
Number · Percentage of participants
Adverse Events, LVEF Function, and Deaths
Percentage of participantsTrastuzumab Emtansine
At least 1 adverse event (AE)98.6
At least 1 serious adverse event10.1
An AE leading to treatment discontinuation13.5
An AE leading to dose delay29.1
An AE leading to dose reduction21.6
Symptomatic cardiac dysfunction0.0
An asymptomatic decline in LVEF2.7
Deaths0
SecondaryPercentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment
Time frame:
From the start to the end of concurrent radiotherapy (up to 51 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment94.9
SecondaryPercentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment
Time frame:
From the start to the end of concurrent hormonal therapy (up to 51 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment69.4
SecondaryPercentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment

Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy.

Time frame:
From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment82.4
SecondaryPercentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay
Time frame:
From the start to the end of radiotherapy treatment (up to 51 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay94.7
SecondaryPercentage of Participants With a Pathological Complete Response

Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery.

Time frame:
Day of surgery
Reported as:
Number · Percentage of participants
Percentage of Participants With a Pathological Complete Response
Percentage of participantsTrastuzumab Emtansine
Percentage of Participants With a Pathological Complete Response56.0 (41.3 to 69.6)
SecondaryDisease-free Survival at Month 12

Disease-free survival was defined as the time from date of first protocol treatment for adjuvant patients or date of surgery for neoadjuvant patients to disease recurrence, occurrence of invasive contralateral breast cancer, other second primary cancer (excluding non-breast second primary), or death, whichever occurred first.

Time frame:
From the start of trastuzumab emtansine for adjuvant patients and from the date of surgery for neoadjuvant patients to 12 months later

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Emtansine—15/148 (10.1%)146/148 (98.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTrastuzumab Emtansine
Atrial fibrillationCardiac disorders2/148
PyrexiaGeneral disorders2/148
Device related infectionInfections and infestations2/148
Febrile neutropeniaBlood and lymphatic system disorders1/148
Abdominal painGastrointestinal disorders1/148
DiarrhoeaGastrointestinal disorders1/148
CellulitisInfections and infestations1/148
Gastroenteritis viralInfections and infestations1/148
Gastrointestinal infectionInfections and infestations1/148
Upper respiratory tract infectionInfections and infestations1/148
Most frequent other events
Showing 10 of 61
Most frequent other events
EventTrastuzumab Emtansine
NauseaGastrointestinal disorders56/148
HeadacheNervous system disorders55/148
EpistaxisRespiratory, thoracic and mediastinal disorders47/148
AstheniaGeneral disorders45/148
PyrexiaGeneral disorders39/148
FatigueGeneral disorders34/148
ArthralgiaMusculoskeletal and connective tissue disorders33/148
ThrombocytopeniaBlood and lymphatic system disorders32/148
MyalgiaMusculoskeletal and connective tissue disorders31/148
VomitingGastrointestinal disorders25/148

Baseline characteristics

Enrolled participant population: All participants enrolled in the study.

Age, Continuous
Age, Continuous(years)Trastuzumab Emtansine
Mean51.1 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Emtansine
Female153
Male0
08

Study locations

44 sites
  • Fort Myers, Florida 33916, United States
  • Lafayette, Indiana 47905, United States
  • Scarborough, Maine 04074, United States
  • Kensignton, Maryland 20895, United States
  • Boston, Massachusetts 02115, United States
  • Boston, Massachusetts 02130, United States
  • Springfield, Missouri 65804, United States
  • Omaha, Nebraska 68114, United States
  • Lake Success, New York 11042, United States
  • Durham, North Carolina 27710, United States
  • Winston-Salem, North Carolina 27103, United States
  • Sioux Falls, South Dakota 57105, United States
  • Nashville, Tennessee 37203, United States
  • San Antonio, Texas 78258, United States
  • Tacoma, Washington 98405, United States
  • Bruxelles, 1000, Belgium
  • Wilrijk, 2610, Belgium
  • Besancon, 25030, France
  • Montpellier, 34298, France
  • Saint Herblain, 44805, France
  • Bielefeld, 33604, Germany
  • Frankfurt am Main, 60389, Germany
  • Hamburg, 20357, Germany
  • Köln, 50931, Germany
  • Mönchengladbach, 41061, Germany
  • Rostock, 18059, Germany
  • Bologna, Emilia-Romagna 40138, Italy
  • Lecco, Lombardia 23900, Italy
  • Milano, Lombardia 20133, Italy
  • Candiolo, Piemonte 10060, Italy
  • San Giovanni Rotondo, Puglia 71013, Italy
  • Perugia, Umbria 06132, Italy
  • Vicenza, Veneto 36100, Italy
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Moscow, 143423, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • Tula, 300053, Russian Federation
  • Barcelona, 08035, Spain
  • Jaen, 23007, Spain
  • Lerida, 25198, Spain
  • Madrid, 28041, Spain
  • Madrid, 28046, Spain
09

References and documents

Publications

  • Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015 Apr 1;33(10):1136-42. doi: 10.1200/JCO.2014.58.7782. Epub 2015 Feb 23. PubMed 25713436 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2010
First posted
Sep 8, 2010
Start
Oct 2010
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jun 26, 2014
Last update
Oct 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01196052
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 8, 2010
Start date
Oct 2010
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jun 26, 2014
Last update
Oct 6, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion